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Gastric cancer imposes a global health burden. Although multimodal therapies have proven to benefit patients with advanced 
diseases after curative surgery, the prognosis of most advanced cancer patients still needs to be improved. Surgical extirpation is 
the mainstay of gastric cancer treatment. Indeed, without curative surgery, variations and combinations of chemotherapy and/or 
radiation cannot bring clinically meaningful success. Centered around D2 surgery, adjuvant and peri-operative multimodal ther-
apies have improved survival in a certain group of gastric cancer patients. Moving toward a personalized cancer therapy era, mo-
lecular targeted strategies have been tested in clinical trials for gastric cancer. With some success and failures, we have learned 
valuable lessons regarding the biology of gastric cancer and the clinical relevance of biological therapies in addition to conven-
tional treatments. Future treatment of gastric cancer will be shifted to molecularly tailored and genome information-based per-
sonalized therapy. Collaboration across disciplines and actively adopting emerging anti-cancer strategies, along with in-depth 
understanding of molecular and genetic underpinnings of tumor development and progression, are imperative to realizing per-
sonalized therapy for gastric cancer. Although many challenges remain to be overcome, we envision that the era of precision can-
cer medicine for gastric cancer has already arrived and anticipate that current knowledge and discoveries will be transformed 
into near-future clinical practice for managing gastric cancer patients.
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INTRODUCTION
Although the overall incidence of gastric cancer has been de-
creasing, it is still one of the most common malignances and 
the leading cause of cancer-related death worldwide: there 
were almost 1000000 new cases and over 720000 deaths in 
2012.1 Geographically, nearly two-thirds of cases are concen-
trated in Eastern Asia, especially, Korea, Japan, and China. 
Over the last couple of decades, efforts to improve the clinical 
outcomes of gastric cancer, including early detection, based on 
nationwide mass screening program,2,3 and to develop strate-
gies, such as radical surgery, chemotherapy, and radiotherapy, 
against gastric cancer have led to improved prognosis of the 
disease.4 However, as populations continue to age, it is expect-
ed that the incidence of gastric cancer will rise and that the 
global burden related to gastric cancer will steadily increase.5 
In addition, unlike early gastric cancer (EGC), which harbors a 
favorable prognosis, advanced gastric cancer (AGC) is still 
challenging; over 50% of patients with AGC experience cancer 
recurrence in their life-time.6,7 There are numerous unsolved 
issues yet to be adequately addressed, and recent progress in 
molecular biology research with cutting-edge biotechnology, 
such as next generation sequencing, is expected to guide per-
sonalized therapy and precision medicine in the field of gastric 
cancer. 
This review focuses on changes in treatment strategies for 
gastric cancer and recent efforts towards precision medicine, 
which is one of the most fascinating key words throughout the 
medical field. We hope that this review can provide insights on 
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the future direction of gastric cancer treatment and translation-
al research. 
SURGICAL TREATMENT OF GASTRIC 
CANCER: THE GOLDEN AGE OF SURGERY 
Radical surgery, a complete surgical resection of macro/mi-
croscopic tumors (R0 resection), is the gold standard for the 
treatment of most solid tumors. In gastric cancer, gastrectomy 
with adequate resection margin and systematic lymphadenec-
tomy is considered to be the only curative treatment. Before 
2000, as several clinical trials failed to show the benefit of addi-
tional chemotherapy after surgery,8-11 gastric cancer was con-
sidered as refractory to chemotherapy. Therefore, surgery 
alone was accepted internationally as standard treatment for 
resectable gastric cancer.12 Thus, the main strategy against gas-
tric cancer has been surgical treatment for a long time. 
Debate for the extent for lymphadenectomy: what is 
the adequate range of lymphadenectomy for gastric 
cancer?
In Japan, where gastric cancer is endemic, the Japanese Re-
search Society for Gastric Cancer (former Japanese Gastric 
Cancer Association) defined and recommended D2 lymphad-
enectomy for gastric cancer in reference to long-term experi-
ence with gastric cancer surgery. Based on a large case review, 
they mapped the location of metastatic lymph nodes accord-
ing to the primary tumor site, and classified metastatic lymph 
nodes into three groups.13,14 Briefly, group 1 indicates perigas-
tric lymph nodes; group 2 includes lymph nodes around major 
vessels in the vicinity of the pancreas and splenic hilum; and 
group 3 indicates lymph nodes beyond group 2. D1 lymphade-
nectomy represents the resection of lymph nodes in group 1, 
and D2 lymphadenectomy refers to the dissection of all lymph 
nodes in group 2, including group 1. This guideline15 has rec-
ommended D2 lymphadenectomy for AGC, and a random-
ized controlled trial (RCT) from Taiwan proved the benefit of 
D2 over D1 lymphadenectomy [5-yr overall survival (OS) was 
59.5% in D2 and 53.6% in D1, p=0.041] in gastric cancer.16 With 
belief that a greater extent of surgery can improve the progno-
sis of gastric cancer (and maybe because there was no addi-
tional option for further improving survival of GC at that time), 
D3 lymphadenectomy (D2+para-aortic lymph node dissec-
tion) was widely applied in Japan and Korea. However, a RCT, 
which compared the outcomes of D2 vs. D3, showed that D3 
surgery was related to a tendency toward increased operative 
complications (20.9% in D2 vs. 28.1% in D3, p=0.07) with no 
improvement in the prognosis of gastric cancer [5-yr OS was 
69.2% in D2 and 70.3% in D3; hazard ratio (HR) of D3 com-
pared to D2 was 1.03, p=0.85].17,18 Thus, the extent of lymphad-
enectomy for gastric cancer was decided at a level of D2, and it 
has remained standard surgical procedure in East Asia.19
On the other hand, in the West, limited lymphadenectomy 
had been considered as standard surgery because two RCTs, 
MRC trial and Dutch Gastric Cancer trial, failed to show the 
survival benefits of D2 over D1 lymphadenectomy.20,21 Even 
worse, D2 surgery was related to un-acceptably high mortality 
(10–13%) and morbidity (43–46%) in these trials.22,23 Conse-
quently, compared to outcomes from East, which reported a 
mortality of less than 1% after D2 surgery,17,24 mortality over 
10% would be difficult to accept in practice. However, 15-year 
follow-up results of Dutch Gastric Cancer trial showed that de-
spite no benefit to OS for D2 surgery, loco-regional recurrence 
(41% in D1 vs. 25% in D2) and lower gastric-cancer-related 
death (48% in D1 vs. 37% in D2) were lower for D2 surgery than 
D1 surgery.25 Moreover, there have been reports26,27 that D2 
surgery can be performed safely (mortality rate was 1.7% to 
3.6%) if it is conducted by experienced-hands in high-volume 
centers, even in the West. Consequently, now D2 surgery for 
gastric cancer is recommended in both East and West guide-
lines with a precondition of being performed at specialized, 
high-volume centers where it can be performed safely.15,28,29 
 
Evolution of total gastrectomy: pancreas and spleen 
preserving gastrectomy
Historically, pancreatico-splenectomy was standard surgery for 
total gastrectomy when cancer is located in the proximal stom-
ach. This was because the extent of D2 lymphadenectomy for 
total gastrectomy includes lymph nodes around the supra-pan-
creatic and splenic hilar area; thus, for removing these lymph 
nodes completely, distal pancreatectomy with splenectomy 
was thought to be mandatory.30 However, a substantial number 
of intraperitoneal abscess and pancreatic fistula occurred as 
unpleasant operative sequels after distal pancreatectomy ac-
companying total gastrectomy. Maruyama, et al.31 reported the 
necessity of pancreas-preserving (PP) total gastrectomy with 
results showing that pancreas preserving total gastrectomy was 
superior to pancreas resection (PR) in terms of morbidity (39.4% 
in PR vs. 19.6% in PP), mortality (0.9% in PR vs. 0.3% in PP), 
5-yr OS (54.5% in PR vs. 70.5% in PP for stage II, and 36.7% in 
PR vs. 54.1% in PP for stage II), and newly developed diabetes 
mellitus (37% in PR vs. 0% in PP). Following results from a RCT 
supported the advantages of total gastrectomy with PP: distal 
pancreatectomy with splenectomy for gastric cancer was relat-
ed to high morbidity and poor prognosis.22 Thus, pancreas pre-
serving total gastrectomy became a standard procedure for ad-
vanced proximal gastric cancer. 
The next question was whether spleen should be removed as 
part of lymphadenectomy in total gastrectomy for proximal 
gastric cancer. Noh, et al. presented the technical feasibility of 
total gastrectomy with spleen preserving hilar lymph node dis-
section at the Second International Gastric Cancer Congress.32 
His data showed that splenectomy during total gastrectomy is 
related to increased morbidity, while providing no survival 
gain.33,34 Following studies supported the results: a study from 
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U.S. reported that splenectomy is related to high operative mor-
bidity and mortality after total gastrectomy;35 a RCT from Korea 
reported that prophylactic splenectomy to remove lymph 
nodes around spleen hilum for proximal gastric cancer is not 
recommended because it offers no prognostic advantages.36 
The incidence of lymph node metastasis at the spleen hilum 
reportedly ranges from 9.8% to 15.4%,37-39 and prophylactic 
splenectomy may not be mandatory, except when the primary 
tumor directly invades the spleen or definite gross lymph node 
metastases is present at the spleen hilum. Nevertheless, organ 
preserving surgery should not mean that necessary lymph 
node dissection can be omitted during radical surgery. Spleen 
preserving total gastrectomy should represent total gastrecto-
my with D2 lymphadenectomy, including splenic hilar lymph 
node dissection, while preserving the spleen. We anticipate 
that an ongoing RCT, the Japan Clinical Oncology Group (JCOG) 
0110-MF trial, will provide more concrete evidence for the on-
cologic feasibility of spleen preserving gastrectomy.40
Increasing proportion of early gastric cancer: the 
propagation of minimally invasive surgery
Minimally invasive surgery (MIS) including laparoscopic and 
robotic surgery is now considered a standard operation in most 
of surgical fields not only for benign surgery but also for cancer 
surgery. In the field of gastric cancer surgery, Kitano, et al.41 re-
ported the first laparoscopic distal gastrectomy for gastric can-
cer, and this procedure has been widely propagated for gastric 
cancer surgery. In the beginning of laparoscopic surgery for 
gastric cancer, conservative surgeons criticized that it would be 
impossible to perform adequate lymphadenectomy through 
laparoscopic devices, so its indication was limited to very early 
stage gastric cancer, in which the extent of lymphadenectomy 
is more limited, compared to AGC. However, cumulative expe-
rience with better laparoscopic surgical devices has shortened 
the gap in surgical quality between conventional open surgery 
and laparoscopic surgery. And its potential advantages [cos-
metic benefit due to smaller incision size, better quality of life 
(QOL), and less pain with shorter hospital stay] and increasing 
incidence of EGC through nationwide mass screening in Korea 
and Japan has bolstered the popularity of laparoscopic surgery 
for gastric cancer. At present, even though RCTs42,43 into the 
oncologic outcomes of laparoscopic surgery for EGC com-
pared to open surgery have not been published yet (KLASS 
and JCOG0912 trial), laparoscopic gastrectomy is considered 
as a possible option for clinical EGC, based on the long term 
result of a large-scale Korean multicenter study.44 However, the 
question about whether laparoscopic surgery can be applied 
for AGC requiring D2 surgery remains unanswered. Although 
reports45,46 have demonstrated the possibility of laparoscopic 
surgery, even for AGC (similar short and long term outcomes 
compared to open surgery), concerns about its potential risks 
and whether similar quality of surgery can be achieved by lap-
aroscopic gastrectomy compared to that of open surgery or not 
(because D2 surgery for AGC is still difficult to perform even 
through an open technique) are still under debate. In an effort 
to diminish those concerns and to expand the indication of 
laparoscopic surgery from EGC to AGC, a multicenter RCT 
(KLASS II, NCT01456598) is ongoing. 
Robotic surgery systems were introduced into the field of 
gastric cancer surgery in 2005 and have propagated, especially 
in Korea, because of their potential advantages over laparo-
scopic surgery: robot systems provide a better three-dimen-
sional view and facilitate fine movements with tremor filtering 
and articular movement.47,48 Most robotic surgeries have been 
performed by experienced laparoscopic surgeons, and it was 
expected that robotic surgery systems would help overcome 
technical difficulties in laparoscopic surgery.49 A meta-analy-
sis,50 which compared the short-term outcomes of robotic sur-
gery to laparoscopic and open surgery for gastric cancer, 
showed that morbidity and mortality were similar and that ro-
botic surgery offers practical advantages of less blood loss and 
hospital stay, compared to open surgery, although operative 
time was longer than other modalities. Even though its high 
cost was criticized, some surgeons have suggested that robotic 
surgery would have advantages over laparoscopic surgery in 
technically difficult and complicated cases (e.g., far advanced 
cancer in which combined resection should be performed for 
R0 resection). Now, its indication in gastric cancer surgery are 
similar to those of laparoscopic surgery,50,51 although concerns 
remain high for whether this expensive approach can be justi-
fied over equivalent but cheaper laparoscopic surgery. 
Efforts to decrease the extent of surgery: more  
minimum to minimum
As the proportion of EGCs has increased and its prognosis is 
quite good,52 enough to be considered as cured in most cases 
after surgery, physicians have now began to focus on improv-
ing QOL of patients with EGC. Consequently, questions of 
whether prophylactic lymphadenectomy for EGC is mandato-
ry have been raised. If there are no metastatic lymph nodes 
around the stomach in EGC, surgeons may be able to spare the 
lymph nodes from surgery and resect only the primary tumor. 
A greater extent of lymphadenectomy leads to more surgi-
cal morbidity and mortality,22,23 and gastrectomy itself can de-
crease QOL of patients. If metastatic lymph nodes could be 
identified before or during an operation, surgeons could spare 
lymph nodes that are noncancerous. Thereby, segmental gas-
trectomy with a safe margin would be possible and would im-
prove QOL of patients without compromising prognosis. Sen-
tinel lymph node biopsy has been widely applied in surgery for 
breast cancer and melanoma. There have also been attempts 
to adapt sentinel lymph node biopsy for gastric cancer surgery. 
Even though the JCOG0302 trial was terminated in the midst 
of enrollment because of its unexpectedly high false negative 
rate,53 another phase II trial from Japan showed the practical 
possibility of sentinel lymph node mapping for gastric cancer.54 
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Evolution of Gastric Cancer Treatment
Based on the lessons learned from both Japanese trials, a new 
phase III clinical trial (SENORITA trial, NCT01804998) of using 
both Tc 99m and indocyanine green injection around tumors 
through intra-operative endoscopy was initiated in Korea after 
a quality control study (NCT01544413).55 The result of this trial 
will guide the possibility of tailored and limited surgery for 
EGC. 
In Japan, endoscopic mucosal resection (EMR) has been ac-
cepted for treating EGC with a very low probability of lymph 
node metastasis and adopted into practice.56 Gotoda, et al.57 
reviewed a large cohort (over 5000 cases) of EGC patients who 
underwent gastrectomy and found that some subgroups show 
a low incidence of lymph node metastasis. Accordingly, the 
authors proposed expansion of criteria for local treatment. De-
velopment of endoscopic devices has made endoscopic sub-
mucosal dissection (ESD) possible, and this new procedure 
has shown better outcomes in en-block resection with a com-
plete resection rate, although with more complications of 
bleeding and perforation.58 Nowadays, EMR and ESD have be-
come viable treatment options for EGC within their indica-
tions and widely adopted across Japan and Korea. Its onco-
logic outcomes, however, compared to surgical resection with 
lymphadenectomy, have yet to reach consensus.59
ADDITIONAL STRATEGIES FOR AGC:  
THE AGE OF CHEMOTHERAPY AND  
RADIOTHERAPY
Unlike the favorable prognosis of EGC, many patients with 
AGC experience tumor recurrence during their lifetime, even 
after radical surgery.6,7,18 Thus, additional strategies are re-
quired to improve the survival of patients with AGC. However, 
numerous trials have failed to show an added benefit for che-
motherapy8-11 to surgery. 
Different strategies against advanced gastric cancer 
for different continents
Macdonald, et al.60 applied combined two strategies, chemo-
therapy and radiation therapy (fluorouracil and leucovorin 
with total 4500 cGy of radiation), after surgical resection of gas-
tric cancer for AGC and compared the outcomes thereof with 
those of surgery alone. A total of 556 patients with resectable 
gastric cancer or gastro-esophageal junction cancer were en-
rolled in this RCT [intergroup 0116 (INT-0116) trial], and the 
results were promising: improved median survival (27 months 
for surgery alone vs. 36 months for additional chemoradio-
therapy group), OS (HR of surgery alone was 1.35, 1.09 to 1.66, 
p=0.005), and relapse-free survival (HR of surgery alone was 
1.52, 1.23 to 1.86, p<0.001) with acceptable incidence of toxic 
effect from chemoradiotherapy. However, only 10 % of the pa-
tients underwent D2 surgery, and 54% of patients received less 
than D1 surgery, igniting a fierce debate over the clinical utility 
of the treatment when D2 surgery is completed. Regardless, 
based on the results, post-operative chemoradiotherapy has 
become standard treatment for resectable gastric cancer in the 
United States. 
Another RCT from the United Kingdom, the Medical Re-
search Council Adjuvant Gastric Infusional Chemotherapy tri-
al (MAGIC), enrolled 503 patients with resectable stomach 
cancer, gastroesophageal junction cancer, and lower esopha-
geal adenocarcinoma and compared the outcomes of peri-
operative chemotherapy (epirubicin, cisplatin, and infused 
fluorouracil) in conjunction with surgery with those of surgery 
alone.61 The results showed the benefit of peri-operative che-
motherapy over surgery alone: better OS (HR of chemotherapy 
group was 0.75, 0.60 to 0.93, p=0.009) and progression-free 
survival (HR of chemotherapy group was 0.66, 0.53 to 0.81, 
p<0.001) with similar postoperative complications (46% in 
chemotherapy group vs. 45% in surgery alone). However, only 
67.8% of patients received curative intent surgery, 24.1% re-
ceived gastrectomy including esophagectomy and 41.4% of pa-
tients underwent D2 surgery. Again, similar debates as with the 
INT-011660 were raised regarding the clinical utility thereof af-
ter D2 surgery. Based on the results, however, peri-operative 
chemotherapy has been applied a standard strategy for AGC in 
Europe. 
Although these two RCTs showed the benefits of additional 
post-operative chemoradiotherapy and peri-operative chemo-
therapy for AGC over surgery alone, the 5-year OS thereof was 
much lower than that of surgery alone in East Asia.18 Thus, a 
question of whether chemotherapy provides additional bene-
fits even after radical surgery (D2 surgery) or not was raised in 
East Asia, where radical D2 surgery is a standard surgery for 
AGC. To answer to this question, two landmark phase III RCTs 
were conducted to compare the outcomes of chemotherapy as 
adjuvant treatment after radical surgery to those of surgery 
alone. The first study to demonstrate the benefits of adjuvant 
chemotherapy after D2 surgery for AGC was the Adjuvant Che-
motherapy Trial of S-1 for Gastric Cancer (ACTS-GC) in Ja-
pan.62,63 A total of 1059 patients with stage II and III disease 
were enrolled in over 100 centers after D2 surgery in this trial. 
The results showed that the prognosis of S-1 monotherapy after 
D2 surgery was better than that of D2 surgery alone regarding 
5-year OS (71.7% in S-1 group vs. 61.1% in surgery only, HR of 
S-1 group was 0.669, 0.540 to 0.828) and 5-year RFS (65.4% in 
S-1 group vs. 53.1% in surgery only, HR of S-1 group was 0.653, 
0.537 to 0.793) with acceptable toxicity (less than 6% of over 
grade 3 toxicity). 
Thereafter, the CLASSIC trial (Capecitabine and Oxaliplatin 
Adjuvant Study in Stomach Cancer), which was conducted at 
37 centers throughout Korea, China, and Taiwan, further sup-
ported the benefits of adjuvant chemotherapy after D2 sur-
gery.6,64 In this study, 1035 patients with stage II and III gastric 
cancer who underwent D2 surgery were enrolled, and capecita-
bine and oxaliplatin (XELOX) were applied as an adjuvant con-
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cept to the XELOX group. The results revealed that adjuvant 
XELOX improved the prognosis of the patients: estimated 
5-year OS was 78% in the XELOX group versus 69% in the sur-
gery alone (HR of XELOX group was 0.66, 0.51 to 0.85, p= 
0.0015) and estimated 5-year DFS was 68% in the XELOX group 
versus 53% in surgery alone (HR of XELOX group was 0.58, 0.47 
to 0.72, p<0.001). In addition, the results of a meta-analysis 
conducted by the Global Advanced/Adjuvant Stomach Tumor 
Research International Collaboration (GASTRIC) group sup-
ported the benefits of adjuvant chemotherapy (pooled HR of 
chemotherapy for OS was 0.82, 0.76 to 0.90, p<0.01 and that of 
DFS was 0.82, 0.75 to 0.90, p<0.01).65 Taken all together, all 
doubts of whether adjuvant chemotherapy after D2 lymphad-
enectomy is needed or not were resolved,66 and adjuvant che-
motherapy has become a standard treatment for resectable 
AGC in East Asia. 
The role of radiotherapy in gastric cancer: is it still 
effective after radical D2 surgery?
The results of the INT- 0116 trial, which showed the benefits of 
chemoradiotherapy, suggested the potential benefits of radia-
tion therapy in gastric cancer, and additional results showed 
that adjuvant chemotherapy improves the survival of AGC pa-
tients. The next question facing clinicians is whether radiation 
could save more patients if added to D2 surgery with adjuvant 
chemotherapy. To address this, the ARTIST trial (Adjuvant 
Chemoradiation Therapy in Stomach Cancer) was conducted 
in Korea.67,68 This RCT assigned 458 patients who underwent 
D2 surgery into two groups: XP group (treated by six cycles of 
capecitabine and cisplatin) and XPRT group (treated by two 
cycles of XP, followed by chemoradiation therapy with capeci-
tabine, and then two additional cycles of XP). After 7 years of 
follow up, the results revealed no significant benefits of addi-
tional radiation therapy (HR of XPRT for OS was 1.130, 0.775 to 
1.647, p=0.5272, and HR of XPRT for DFS was 0.740, 0.520 to 
1.050, p=0.0922). It is has been argued that radiation therapy is 
a loco-regional treatment rather than systematic treatment, 
and D2 surgery would be enough for loco-regional control of 
gastric cancer. Therefore, the addition of radiation therapy to 
D2 surgery would have no further benefit. Interestingly, sub-
group analyses showed a possible benefit of XPRT over XP re-
garding DFS in lymph node positive and intestinal-type gastric 
cancer. The ARTIST-II successor trial is currently evaluating 
the benefits of adjuvant XPRT in patients with lymph node 
metastasis after D2 surgery. 
Target therapy for gastric cancer: its successes and 
failures 
One of the problems of traditional chemotherapy is that it acts 
against all actively proliferating cells, normal and cancerous, 
causing serious collateral damage. Thus, treatments against 
targets specific to cancer cells could spare normal cells. Al-
though understanding of the molecular genetic underpinnings 
of gastric cancer has lagged behind that for other solid cancers, 
recent efforts to better understand gastric cancer biology has 
led to the discovery of a handful of genetic alterations specific 
to cancer cells: overexpressed proteins are present in cancer 
cells but not in normal cells, and specific mutant proteins drive 
cancer growth and survival. 
The precedent success of target therapy by trastuzumab, a 
humanized monoclonal antibody interferes human epidermal 
growth factor receptor type 2 (HER2/neu/ErbB2), for HER2 
positive breast cancer encouraged the expanding of its indica-
tions to gastric cancer. The Trastuzumab for Gastric Cancer 
(ToGA) trial, a RCT of patients with HER2 positive mostly met-
astatic gastric/gastro-esophageal cancer, was conducted in 122 
centers in 24 countries.7 A total of 549 patients were randomly 
assigned into two groups: trastuzumab with chemotherapy 
and chemotherapy alone. The results showed that trastuzum-
ab improves the prognosis of HER2 positive gastric cancer; 
the median OS of trastuzumab with chemotherapy was 13.8 
months versus 11.1 months in chemotherapy alone (HR of 
trastuzumab with chemotherapy was 0.74, 0.60 to 0.91, p= 
0.0046). The success of the ToGA trial suggested that cancer bi-
ology-driven target therapies could be possible in gastric can-
cer and encouraged investigations into additional candidate 
targets for AGC. 
The next target evaluated was vascular endothelial growth 
factor (VEGF), which is known to be related to angiogenesis in 
tumorigenesis. Treatment with bevacizumab, a humanized 
monoclonal antibody that inhibits VEGF, exhibited a positive 
impact among patients with several types of cancers, such as 
colorectum,69 lung,70 and recurrent glioblastoma.71 Also, a 
phase II trial to evaluate the safety and efficacy of bevacizum-
ab with conventional chemotherapy (doxetaxel, cisplatin, and 
fluorouracil) for advanced gastro-esophageal cancer seems to 
have been successful.72 Expecting continued success, the Avas-
tin in Gastric Cancer (AVAGAST) trial for evaluating the effica-
cy of additional bevacizumab to chemotherapy (capecitabine 
and cisplatin) as the first-line treatment for unresectable AGC 
was conducted.73 This double blind, placebo-controlled phase 
III RCT enrolled 774 patients. The primary endpoint of improv-
ing OS, however, was not satisfied (median OS was 12.1 months 
in adding bevacizumab group vs. 10.1 months in placebo plus 
chemotherapy group; HR of adding bevacizumab was 0.87, 
0.73 to 1.03, p=0.1002), although progression free survival and 
overall response rates were significantly better for adding bev-
acizumab over the placebo group. A subsequent biomarker 
evaluation study, which analyzed blood and tumor tissue 
samples collected for the AVAGAST trial reported that VEGF-
A and tumor neurophilin-1 (NRP1) could be potential predic-
tive biomarkers for bevacizumab efficacy.74 The most recently 
reported REGARD study, an international Phase III RCT for 
assessing the clinical benefit of VEGF receptor 2 (VEGFR-2) 
inhibition in gastric and gastroesophageal cancer, showed 
promising results for angiogenesis blockade therapy in gastric 
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cancer.75 The study showed that patients assigned to treatment 
with ramucirumab, a fully humanized IgG1 monoclonal anti-
body inhibitor of VEGFR-2, had significantly improved survival 
(HR 0.776, 95% CI 0.603–0.998, p=0.047), with a median surviv-
al of 5.2 months versus 3.8 months with placebo. Still, there are 
many questions regarding the results for the AVAGAST and 
REGARD trials. In AVAGAST trial, it seemed that Asian patients 
were less benefited from bevacizumab compared to patients 
in the rest of the world, and in biomarker study of the trial 
showed that those biomarkers, VEGF-A and NRP1 were not ef-
fective to predict responsiveness of bevacizumab. In REGARD 
trial, however, the proportion of Asian patients enrolled was 
only around 8%. This is largelry due to the practical reason: 
2nd line chemotherapy is considered standard of care in Asia. 
Togetehr, the resutls of the two pivotal trials on anti-angiogen-
esis treatment for gastric cancer imply that understanding of 
heterogeneity in gastric cancer across the globe76 including 
ethnicity could impact the biologically targeted therapies for 
this disease. Regardless, the data impose a significant clinical 
insight of targeted biological options in selected patients’ sub-
populations with corresponding target presence. 
NECESSITY OF PERSONALIZED THERAPY 
IN GASTRIC CANCER TREATMENT: THE 
PROLOGUE OF PRECISION MEDICINE 
FOR GASTRIC CANCER
Despite the successes of some clinical trials, which showed the 
benefits of chemotherapy, the effect size of benefit was just 
around 10–20%,6,18,62-65 and this number is somewhat disap-
pointing. This implies that current standard chemotherapy is 
effective in only a small subgroup of patients, which might be 
explained by the heterogeneity of the disease. If we can predict 
who will and will not respond to chemotherapy, physicians 
can treat patients more effectively and spare some from un-
necessary chemotherapy. Indeed, practicing this on a routine 
basis is the ultimate goal of personalized and precision cancer 
medicine. Precision medicine is defined by the National Acad-
emy of Sciences as “the use of genomic, epigenomic, exposure, 
and other data to define individual patterns of disease, poten-
tially leading to better individual treatment”.77 This concept is 
not new, as Hippocrates, who is the father of modern medicine 
said, “It’s far more important to know what person the disease 
has than what disease the person has.” 
In tradition, anatomic site and histology based classifica-
tions, such as the Lauren78 and World Health Organization79 
classifications, have been widely used to classify gastric cancer. 
However, these systems are not good enough to classify prog-
nosis and/or predicting chemo-responsiveness. Another po-
tential candidate marker for predicting prognosis and chemo-
responsiveness in gastric cancer is microsatellite instability 
(MSI). The loss of function of mismatch repair (MMR) genes 
can cause cancer, and colon cancer with MSI is known to be 
related to good prognosis after surgery alone and be refractory 
to fluorouracil-based chemotherapy.80,81 In gastric cancer, it 
was reported that the characteristics of gastric cancer with MSI 
are similar to those of colon cancer;82-84 however, these results 
need to be validated across distinct populations. 
There has been numerous efforts to classify gastric cancer 
based on molecular characteristics over anatomical classifica-
tion. Among others that have tried to define subgroups of gas-
tric cancer,85-87 Tan, et al.88 described the possibility that gastric 
cancer could be divided into intrinsic subtypes (genomic in-
testinal and genomic diffuse) according to gene expression 
profiles and that the subtypes might be of use in predicting 
prognosis and customized therapy. Recently, The Cancer Ge-
nome Atlas Research Network reported the results of molecu-
lar classification of gastric cancer through integrative genomic 
analyses, which suggested that gastric cancer could be divided 
into four subtypes: 1) Epstein-Barr virus-related tumors that 
exhibit recurrent PIK3CA mutation, hypermethylation of DNA, 
and overexpression of PD-L1/2; 2) MSI represented by elevat-
ed mutation rates and MLH1 silencing, which is one of the main 
MMR genes; 3) genomically stable tumors that are strongly re-
lated with diffuse histology, RHOA mutations, and CLDN18-
ARHGAP fusion; and 4) chromosomal instability that mainly 
comprise intestinal histology, TP53 mutation, and focal ampli-
fication of receptor tyrosine kinases.89 Further, another study 
reported that gastric cancer can be classified into four molecu-
lar subtypes as follows: microsatellite unstable, microsatellite 
stable (MSS) with/without TP53 mutation, and MSS with epi-
thelial-to-mesenchymal transition (EMT) type. They found 
that the MSS/EMT type of gastric cancer was related to poor 
prognosis, early-aged onset, and the highest risk of cancer re-
currence.90 These results imply that gastric cancer can be clas-
sified according to its molecular characteristics and that these 
classifications can indicate which types of gastric cancer will 
be responsive to standard treatment and which types will be 
refractory, potentially guiding tailored options for individual 
patients. 
FUTURE PERSPECTIVES
Despite extraordinary efforts to improve the prognosis of gas-
tric cancer over the last couple of decades, we still have a long 
way. Recent advancements in cancer biology and biotechnol-
ogy, including technology of sequencing and its interpretation, 
have set in motion the realization of personalized and preci-
sion medicine into clinical practice.91 In the United States, a 
precision medicine initiative has been announced and will be 
supported by more than 215 million USD. The initiative is ex-
pected to accelerate efforts to realize precision medicine, such 
that the genetic make-up of tumors, individual patient varia-
tions, and environmental factors can be taken into account in 
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clinical care decision making processes. To realize precision 
medicine in gastric cancer, comprehensive characterization of 
molecular mechanisms and identification of driver genetic al-
terations for individual patients are imperative. Although these 
once seemed formidable challenges, we are now closer to the 
future of biomarker-based stratification of gastric cancer pa-
tients and application of targeted therapeutics more than ever. 
Finally, immunotherapy, the next generation of anti-cancer 
strategies (after surgery, chemotherapy, and radiation thera-
py), targeting immune checkpoints of cancer, has been actively 
evaluated in clinical trials and applied in clinical practice for 
selected cancer types.92,93 With all the old and new armamen-
taria, we need to continuously integrate and adopt state-of-
the-art strategies across all disciplines to fight against gastric 
cancer. Precision medicine is at our fingertips, and we are on 
the verge of conquering gastric cancer. 
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